Management of Local Reactions to Intravenous Iron Infusions

Introduction to Local Reactions

Local reactions, such as bruising and tenderness, are generally mild and self-limiting, but should be monitored to ensure they don't progress to more serious complications, as recommended by the American Journal of Hematology 1
Proper technique, including ensuring secure IV placement before starting infusion and following formulation-specific guidelines for dilution, can minimize local reactions, according to the American Journal of Hematology 1

If bruising or tenderness develops during administration, the infusion should be stopped, and the site should be monitored for 15 minutes to assess if symptoms resolve, as recommended by the American Journal of Hematology 1
Rechallenge at a slower infusion rate (50% of initial rate) can be considered if symptoms resolve, as suggested by the American Journal of Hematology 1
Cold compresses, elevation of the affected limb, and monitoring for progression of symptoms can help reduce inflammation and bruising, while antihistamines or vasopressors should be avoided for simple local reactions, according to the American Journal of Hematology 1

Different iron formulations have varying side effect profiles, such as Iron Dextran causing dose-related arthralgias and myalgias, as reported in the American Journal of Kidney Diseases 2
A different iron formulation should be considered for future infusions if a patient experiences significant bruising or tenderness, as recommended by the American Journal of Hematology 1
Formulations with lower reaction rates, such as ferric carboxymaltose, should be considered if previous reactions occurred, and recommended infusion rates should be followed, such as up to 1,000 mg in 15 minutes, as per the European Journal of Heart Failure guidelines 3
Iron sucrose should be administered at 200-500 mg over 30-210 minutes, while ferric gluconate should be administered at a maximum of 125 mg over 60 minutes, as per guidelines from a reputable medical source 4

Patients should be informed about the possibility of bruising and tenderness at the infusion site, and that these reactions are generally mild and self-limiting, as recommended by the American Journal of Hematology 1
Patients should be advised to report worsening symptoms, such as increasing pain, spreading redness, or fever, and that local reactions typically do not contraindicate future iron therapy, as stated by the American Journal of Hematology 1
Patients should be educated on the potential for delayed reactions that may occur hours to days after infusion, and should be monitored for 30 minutes after infusion, as recommended by the American Journal of Hematology 1
Patients should be informed that bruising is not among the most common side effects of iron infusions, which typically include dizziness, headache, hypertension, hypophosphatemia, injection-site reactions, and nausea, as stated by the European Journal of Heart Failure guidelines 3